TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Elizabeth Carideo CunniffYosuke SatoDoanh MaiVicky A ApplemanShinji IwasakiVihren KolevAtsushi MatsudaJudy ShiMichiyo MochizukiMasato YoshikawaJian HuangLuhua ShenSatyajeet HaridasVaishali ShindeChris GemskiEmily R RobertsOmid GhasemiHojjat BazzaziSaurabh MenonTary TraorePu ShiTennille D ThelenJoseph ConlonAdnan O Abu-YousifChristopher ArendtMichael H ShawMasanori OkaniwaPublished in: Cancer research communications (2022)
TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.